[1] While phthalates are not authorized as food additives, they have been shown to migrate to food and beverages from even non-PVC food contact materials ... phthalates into a single class failed ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

A government watchdog examining the FDA’s accelerated approval pathway has released a 32-page report (PDF) that concludes the agency’s controversial endorsement of Biogen’s failed Alzheimer ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in positive trial results that could set it up for a full approval.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Journavx is one of three recently approved drugs in Vertex Pharmaceuticals' product lineup. The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan ...

Jan. 21, 2025 -- The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed. The drug ...

Jan 21 (Reuters) - The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's (JNJ.N), opens new tab nasal spray, Spravato, to allow it to be used as a standalone treatment ...

The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery. Pain is registered in ...